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The aim of this study was to validate and report the factorial analysis of the World Health 
Organization’s 5-item Well-being Index (WHO-5) among outpatients with type 2 diabetes. 
We investigated the psychometric properties of the WHO-5 and its suitability for identifying 
potential depressive symptoms in Polish adults with diabetes.  
Methods 
Participants were randomly chosen among Polish diabetes outpatients and invited to 
participate in the cross-sectional study (N = 216). Participants completed the Polish version of 
the WHO-5, Problem Areas in Diabetes Scale and Patient Health Questionnaire. 
Results 
Factor analyses identified the one-factor structure of the Polish version of the WHO-5. The 
internal consistency of the Polish version of the WHO-5 is satisfying. With regard to 
convergent validity, there were significant negative associations between the WHO-5 and 
PAID, the PHQ-9, HbA1c and the amount of medical complications. The AUC indicates that 
the WHO-5 is an effective measure for identifying depressive symptoms. The optimal cut off 
values of ≤12 yielded the best sensitivity/specificity trade-off for identifying depression 
among people with diabetes. 
Conclusions  
The Polish version of the WHO-5 is a reliable, valid outcome measure for outpatients with 
type 2 diabetes and can be a useful instrument for screening for depression in people with 
diabetes. 
KEYWORDS: Diabetes Mellitus, Type 2, Depression, World Health Organization, 






In European diabetology, the objectives and methods formulated in the Declaration of 
St. Vincent, which was signed in 1989 under the auspices of the World Health Organisation 
and the International Diabetes Federation, were accepted as the basis for all activities in the 
care of people with diabetes [[1], [2]].  This document, including recommendations and 
guidelines directed at improving the health care and social conditions of people with diabetes, 
was also adopted by the Polish Government. 
It is clear that intensive diabetes care reduces the risk of developing chronic 
complications of diabetes, disability and mortality [1]. The Declaration of St. Vincent 
included guidelines aimed at improving psychological well-being among people with diabetes 
which was based on the assumption that psychological well-being is associated with physical 
well-being, and thus may impact on diabetes [2], [3]. Indeed, empirical evidence has 
demonstrated that improving psychological well-being can enhance clinical outcomes 
including metabolic control or complications risk reduction [4][5][6], [7].  
For that reason, the monitoring of well-being among people with diabetes is one of the 
recommended goals of diabetes management. The prevalence of depression in people with 
diabetes is about twice as high as the general population [8]. 
The severity of depressive symptoms is related to functional impairment as well as 
higher costs of care in people with diabetes [5], less than the optimal diabetes self-
management, including lower levels of physical activity and difficulties with self-medication  
[9], [10], [11] and with hyperglycaemia [6]. Lower levels of physical activity and poorer 
control of diabetes results in greater risk of poor microvascular and macrovascular outcomes 
and higher mortality [12], [13].  
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The monitoring of psychological well-being can increase the efficacy of identifying 
psychological problems and facilitate the treatment of these problems resulting in improving 
the psychological and physical condition of people with diabetes [14]. It is critical, therefore, 
to routinely screen for depressive symptoms and well-being in people with diabetes using 
standardized measures.  
 Short, simple screening instruments are useful in quickly and systematically 
recognizing people experiencing significant depressive symptoms, however at present the 
detection of mental health problems such as depression or anxiety by physicians and nurses 
does not reach more than 50% [15]. Brief self-report screening instruments for depression are 
available such as the Beck Depression Inventory (BDI) [16], the Hamilton Rating Scale for 
Depression [17],  and the Patient Health Questionnaire Nine (PHQ-9) [18].  
Additionally, some simple tools for identifying diabetes-specific psychological 
problems and distress also exist, for example the Problem Areas in Diabetes Scale (PAID) 
[19]. All the aforementioned instruments are psychometrically reliable, short and easy to use 
in clinical practice for identifying depressive symptoms [20].  However, the appropriateness 
of using screening tools characterized by negatively phrased questions [21] especially where 
issues of acceptability are important (e.g. among non-psychiatric populations) has been 
highlighted recently [21], [22]. It has been suggested that the negative content of the questions 
may reduce acceptance resulting in withdrawing participation in the screening and diagnosis 
process [21]. In consequence the comprehensive diagnosis and accurate prediction of 
outcomes is often overlooked. In contrast, tools that include positive statements (e.g. asking to 
what extent the person has felt calm, relaxed and cheerful) are often more acceptable and can 
lead to a correct diagnosis of depressive symptoms as identified by the absence of positive 
mood [23].  
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The Well-being Index five item (WHO-5) [24] is one of such instruments. Results of 
empirical studies show that it is also useful for identifying depressive symptoms because the 
items included in this tool represent the lack of positive mood, interest and energy [25], [26] 
which  correspond to some of the symptoms of depression. Evidence has demonstrated that 
the WHO-5 has good sensitivity and specificity regarding the prediction of major depression 
[27], including among people with diabetes [14], [22], [24], [28], [29]. 
Hence, the main aim of this study was to investigate the psychometric characteristics 
of the Polish version of the WHO-5 among Polish adults with diabetes. We examined the 
factorial structure of this tool, the internal consistency, reliability, its sensitivity and 
specificity for detecting depression using the standardized structured interview MINI 
International Neuropsychiatric Interview [30], [31] (Polish version 5.0.0).  
We assumed that the Polish version (like other language versions of the WHO-5) has a 
single factor structure and satisfactory psychometric properties as well as a high sensitivity 
and specificity for diagnosing depression.  
2. MATERIAL AND METHODS 
The data analysed in this study is derived from the INTERPRET-DD study that was a 
collaborative study carried out between January 2014 and June 2015 among invited outpatient 
clinic attendees with Type 2 diabetes in 14 different countries [32]. The investigators were 
recruited from leading centres of excellence in Poland and included psychiatrists. The 
diabetologists in diabetes clinics invited individuals to participate in the study. Written 
informed consent was obtained from all participants. 
2.1. Participants 
The study included individuals diagnosed with type 2 diabetes at least 12 months prior 
to participation in their diabetes outpatient facilities. The participants were aged between 18 
and 65 years [33]. Individuals with type 2 diabetes diagnosed for less than 12 months were 
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excluded from the study. Other exclusion criteria were: diagnosis of type 1 diabetes; 
uncompleted set of measures due to communication and/or cognitive difficulties; any life-
threatening or severe conditions, such as cancer or stroke in the last 6 months. In order to 
maintain homogeneity of the group those currently admitted or planning admission for 
inpatient care to a hospital were excluded, because they might get a more intensive or 
different treatment. The additional exclusion criteria were pregnancy or childbirth in the last 6 
months, clinical diagnosis of alcohol or other substance (not tobacco) dependence or a 
diagnosis of schizophrenia. The data delivered only from Poland was used in the analysis. At 
total of 216 individuals with type 2 diabetes (100 females, 116 males) took part in this study 
(see Table 1). 
2.2. Procedure 
At the first step, each eligible individual completed a survey recording age, duration of 
diabetes, family history of diabetes and presence/history of diabetes complications 
(cardiovascular disease, retinopathy, peripheral neuropathy, peripheral vascular disease, renal 
disease and associated disorders), the most recent blood pressure measurement, HbA1c, as 
well as height and weight. 
Each of the participants completed the Patient Health Questionnaire (PHQ-9) [18], 
World Health Organization-Five Well-Being Index (WHO-5) questionnaire [34] and the 
Problem Areas in Diabetes (PAID) scale [19]. The translation of the WHO-5, PAID and 
PHQ-9 was carried out using standard forward/back-translation procedures. In addition, 
Polish investigators ensured that it was culturally applicable through a discussion on the 
contents of translated items and testing them with a range of healthcare professionals and 
people with type 2 diabetes, focusing on the semantic meaning of expressions and language. 
In order to identify the occurrence of a current major depressive disorder (MDD) a 
MINI International Neuropsychiatric Interview [30] was subsequently conducted. Any 
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medications for mental health problems or documented diagnosis or treatment of any 
psychiatric condition were recorded. Participants were also asked about the location of their 
accommodation (rural or urban area), level of education (no formal, some/completed primary, 
some/completed secondary school, or higher education), marital status (married/cohabiting vs 
being single/widowed/divorced) and financial status. 
2.3. Measures 
To validate the Polish version of WHO-5, the relevant data were extracted from the 
International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study 
dataset [33]. We took into consideration the patient’s results in the PHQ-9 and the PAID 
scales which were used as external scales to verify convergent validity of the Polish version of 
WHO-5.   
The WHO-5 is a unidimensional, five-item tool used to measure general emotional 
well-being in the past two weeks [28]. Participants are asked to rate how often they have felt 
on a 6-point Likert Scale ranging from 0 (not at all) to 5 (all of the time). The scores are 
summed with higher scores indicating better emotional well-being. All of the items are 
positively worded statements (e.g. “I have felt cheerful and in good spirits). Thus, the raw 
score ranges from 0 (absence of well-being) to 25 (maximal well-being). A raw score below 
13 (< 12) indicates poor well-being. Raw scores may also be transformed to a percentage 
value from 0 to 100 by multiplying the raw score by 4 [27]. The English version of the WHO-
5, and its many translations, including Polish version, are available at https://www.psykiatri-
regionh.dk/who-5/who-5-questionnaires/Pages/default.aspx. It is recommended to administer 
the Major Depression (ICD-10) Inventory if the raw score is below 13 or if the patient has 
answered 0 to 1 to any of the five items [34]. With regard to populations with diabetes, the 
majority of studies have employed self-report tools such as the PHQ-9 or the Centre for 
Epidemiological Studies Depression Scale (CES-D). The cut-off scores on both these 
9 
 
instruments that indicate likely depression have been shown to correspond with WHO-5 
results [27], [28], [35], [36]. It is noteworthy, that other studies have identified other cut-offs 
for likely depression [27]. For example, in a study carried out by Hajos et al. [36] when a 
PHQ-9 score of ≥ 10 or ≥ 12 are the criterion for depression, a WHO-5 score of 48 (≤ 12 raw 
scores) and 46 (< 12 raw scores) yield the optimal trade-offs between sensitivity and 
specificity respectively. To our knowledge only the one study has used DSM-IV depression 
criteria as assessed by a structured interview as the gold standard reference among 
participants with diabetes [29]. However, in this study sensitivity/specificity trade-off was 
presented only for the conventional WHO-5 cut-off point of <13 (indicating poor well-being) 
and we do not know the sensitivity and specificity for alternative cut-offs. This is important 
because the sensitivity and specificity values vary for a cut-off of <13 (<50) across the 
studies. The sensitivity ranges from 0.57 to 1 and specificity from 0.78 to 0.88 [27]. For 
example, the study carried out among people with diabetes in Japan showed that the WHO-5 
had a sensitivity of 0.57 and specificity of 0.83 for the conventional cut-off point (≤ 13 points) 
[35]. On the other hand, using the same cut off point among paediatric outpatients in the 
Netherlands resulted in a sensitivity of 0.89 and specificity of 0.86 [28]. These discrepancies 
indicate the necessity of evaluating the cut-offs for individual countries and populations; the 
usefulness of unified cut-offs irrespective of the specificity of the population seem to be 
limited. 
We used the PHQ-9 [18] to assess the severity of depressive symptoms. The 
participants rate the frequency of the presence of depressive symptoms from 0 (not at all) to 3 
(nearly every day). The value of the Cronbach’s α in this sample yielded 0.86. 
The PAID scale [19] consists of 20 statements regarding the existence of negative 
states commonly experienced by people with diabetes (e.g. “worrying about the future and the 
possibility of serious complications”). Participants report the extent to which each issue is 
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currently a problem for them on a 4-point Likert scale (from 0 – not a problem to 3 – a serious 
problem) According to the Polish version of the PAID we included single factorial structure 
of this tool in the analysis. The Cronbach’s alpha obtained was α = 0.95. 
The diagnostic status of all the participants at the time of the WHO-5 assessment was 
determined by the MINI International Neuropsychiatric Interview (Version 5.0.0) [30], [31] 
which has been widely used among different populations, including those with serious 
illnesses. It is a reliable diagnostic instrument according to Diagnostic and Statistical Manual 
of Mental Disorders 5th edition (DSM-5) criteria [30]. The interview was conducted by a 
trained Psychiatrist. The classification of depressed or non-depressed was based on DSM-IV 
criteria for current Major Depressive Disorder (MDD). 
2.4. Statistical analyses 
2.4.1. Factorial structure, internal consistency reliability and convergent validity of the 
Polish version of the WHO-5. 
The statistical analyses were carried out using SPSS version 25 for Windows. In order 
to determine the factorial structure of the Polish version of the WHO-5, an Exploratory Factor 
Analysis with Oblimin rotation was conducted. Principal axis factoring (PAF) method was 
applied because of the result of Kolmogorov-Smirnov test indicating non-normal distribution 
of the data. The recommended value of factorial loadings of every item is above 0.3 [37].  
The internal consistency reliability of the WHO-5 was assessed using Cronbach’s 
alpha with α values between 0.80 and 0.90 usually indicating good internal consistency [38]. 
To measure convergent validity, Pearson product moment correlations were applied. We 
assumed that WHO-5 scores would be negatively associated with PHQ-9 results and 
negatively related to PAID scores. A strong or moderate strength of the relationship (r value 
from |0.50| to |0.80|) between WHO-5 scores and these two measures indicates satisfactory 
convergent validity [39].  
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2.4.2. Screening accuracy for likely depression. 
In order to assess the discriminatory validity of the Polish version of the WHO-5 as a 
screening tool for current depressive episodes, the positive predictive value (PPV) and 
negative predictive value (NPV) were calculated using logistic regression. The PPV is the 
probability of disease for positive test results while the NPV means the probability of being 
healthy when test results are negative [40]. Then, we employed a Wald statistic estimated for 
the depression indicator variables from a logistic regression model to test whether the 
variation in the prevalence rate of persistent depression across the level of well-being is 
different than expected by chance. Odds ratios (ORs) and their confidence intervals (CI) were 
estimated.  
In this study the results of the WHO-5 are reported on a continuous scale, therefore the 
sensitivity and specificity can be computed across all the possible threshold values. The 
sensitivity and specificity depend on the value of the threshold and the sensitivity is inversely 
related with specificity [40], [41]. To determine sensitivity and specificity of the WHO-5, 
Receiver Operating Characteristic (ROC) curve was mapped and the area under the curve 
(AUC), as an effective measure of accuracy of the WHO-5 for identifying depression has 
been calculated. In previous studies researchers have not reported the applied criteria for the 
choice of optimal cut-off [28], [29], [35], [36]. We identified the optimal cut off values using 
Youden’s index which ranges between 0 to 1, with higher values indicating greater diagnostic 





3.1. Demographic, clinical and psychological sample characteristics 
The demographic, clinical, and psychological characteristics of the participants are 
presented in Table 1.  
The mean age of participants was 57.43 (SD = 7.30) ranged between 18 and 65 years 
with a mean duration of diabetes of 9.47 (SD = 7.10) years. The mean WHO-5 scores for total 
sample was 15.97 (SD = 6.48; range 0 – 25). WHO-5 scores were not significantly associated 
with age (r = 0 .11, p = 0.11). There was also no difference according to either gender (t(214) 
= 1.29, p = 0.20), education level (H(2) = 1.669, p = 0.44) or  location of residence (U = 
1559.50, p = 0.13). WHO-5 scores were not significantly associated with diabetes duration (r  
= -0.11, p = 0.11). 
Table 1 around here 
3.2. Reliability and validity 
The analysis indicated one factor of the Polish version of the WHO-5 with eigenvalues 
> 1.0 (3.36; second highest value is .58). The inspection of the scree plot also suggested a 
one-factor structure (see Figure 1).  
Figure 1 around here 
 
Figure 1. Scree plot of the Polish version of the WHO-5. 
 
The one-factor solution indicated that factorial loading of each of the five items is 
above the recommended minimal value of 0.3 [37] and all factor loadings are 0.76 or higher. 
The total variance of the one-factor solution was 67.28% (see Table 2). 




In the next step, we assessed the reliability of the WHO-5 scale by calculating the 
Cronbach’s alpha reliability coefficients. Cronbach’s alpha for the Polish version of this tool 
yielded 0.87. Thus, the internal consistency reliability of the WHO-5 is satisfactory, 
indicating the homogeneous structure of the measure.  
In terms of convergent validity WHO-5 scores indicated a strong significant inverse 
correlation with the PHQ-9 (whole group: r = -0.75, p < 0.001) and a strong negative 
correlation with PAID scores (r = -0.52, p < 0.001). Additionally, there was a significant 
negative correlation between WHO-5 scores and HbA1c (r = -0.18, p < 0.05). The 
relationship between WHO-5 and the amount of medical complications was also significant 
(rs = -.184, p < 0.05). The medical complications including: stroke or cerebrovascular 
incident, heart attack or myocardial infarction, any other heart trouble (e.g. angina etc), 
retinopathy, macular oedema, neuropathy, nephropathy, peripheral vascular disease, heart 
disease/ heart problems, kidney problems, problems with legs / feet, high blood pressure, high 
cholesterol. These results demonstrate a good convergent validity of the Polish version of the 
WHO-5. 
 
3.3. Screening accuracy for depression 
The logistic regression analysis indicated that the model containing the WHO-5 as a 
predictive factor for a major depressive episode was statistically significant, χ2(1) = 111.32; p 
< 0.001. The Hosmer–Lemeshow test indicated goodness of fit of the prediction model, H-L 
χ2(7) = 0.89; p = 0.996. The coefficient of determination Nagelkerke's R squared, R2 = 0.71 
indicated that approximately 71% of the variability in the MDD is explained by the WHO-5 
scores. The Wald test showed that the variation in the prevalence of major depressive disorder 
across the level of well-being is more varied than expected by chance, W(1)=35,23; p < 0,001 
(OR =  0.617; 95%CI: 0.526 – 0.724). 
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The ROC curve was mapped to determine the sensitivity and specificity of the WHO-5 
for the detection of a current major or minor depressive episode according to the Polish 
version of the WHO-5 total score (see Figure 2).  
Figure 2 around here 
Figure 2. ROC curve of the WHO-5 for detecting likely depression in adults with type 2 
diabetes (N = 216). 
The AUC was 0.965; p < 0.001 (95%CI 0.940–0.989). The Youden's index (0.802) 
indicated that a cut-off of ≤12 yielded the best sensitivity/specificity trade-off: sensitivity 
93.8%; specificity 86.5%; PPV 54.5%; and NPV 98.8% (see Table 3).  
Table 3 around here 
 
4. DISCUSSION 
This is the first study to identify the psychometric properties of the Polish version of 
the WHO-5 and its utility as a suitable screening tool for depression among Polish adults with 
type 2 diabetes. The results of our analysis provide empirical evidence for the internal 
consistency, reliability and convergent validity of the Polish version of the WHO-5, with a 
high Cronbach’s alpha and expected strong negative associations with the PAID and PHQ-9. 
We observed a weak negative relationship between WHO-5 scores and HbA1c as well as 
between WHO-5 scores and the amount of medical complications. Additionally, the results of 
Principal Axis Factoring (PAF) support a one-factorial structure of the WHO-5, which 
confirms the findings of other research in people with diabetes [22], [28], [36], as well as the 
Danish general population [24]. 
The ROC analysis supports the use of the WHO-5 as a screening tool for verifying 
likely depression in people with type 2 diabetes. The AUC was very close to 1, suggesting a 
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good accuracy of the WHO-5 for screening for depression. It also had high sensitivity and 
specificity for the optimal (≤12) cut-off value. According to our knowledge, this is the first 
study applying Youden’s index to find the optimal cut-off values among people with diabetes, 
making an important contribution to existing work where discrepancies in the sensitivity and 
specificity for the conventional cut-off of < 12 have been found up to now [27]. Furthermore, 
unlike our research, the majority of previous studies did not compare the WHO-5 with a 
structured diagnostic interview and so should be interpreted with caution. For this reason, we 
diagnosed depression using DSM-IV criteria assessed by a structured interview (the M.I.N.I) 
as the gold standard reference. 
International guidelines recommend routine screening for depression in people with 
diabetes [43], [44]. However, although there is strong evidence that up to 10-20% of people 
with type 2 diabetes may have depression, this often goes unrecognized [15]. This may be 
partly explained by healthcare professionals often reporting being insufficiently equipped to 
provide diabetes self-management education, including emotional and psychological aspects 
of diabetes [45]. The absence of psychological services is considered as the most significant 
barrier in recognizing mental problems and providing people with adequate treatments [46]. 
However, it is unlikely that both expanding the diabetes team with specialist psychological 
expertise and providing mental health professional, as an integral part of the team will be 
resolved in the short term [47]. Thus, providing a screening tool for depression which 
healthcare professionals will find easy to use may improve recognition of depression among 
patients with diabetes [45]. This may contribute to providing more complex, appropriate 
treatment or support leading to health enhancing or quality of life improvements, reducing the 
adverse impact of depressive symptoms on diabetes management, glycaemic control and other 
health outcomes [48]. The WHO-5 has been useful as an outcome measure among various 
clinical groups [27]. For example, Wade et al. [49] applied the WHO-5 to measure the 
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efficacy of a prolonged release melatonin formulation among people with insomnia. Among 
people with breast cancer the WHO-5 was used to test the effect of mindfulness-based therapy 
[50]. In turn, Robinson et al. [51] examined the effect of paroxetine among individuals with 
tinnitus using the WHO-5 as one of the outcome measures. The extensively applicability of 
the WHO-5 as a valid screening tool for depression in geriatrics [52], neurology [53] and 
endocrinology [29], [35], [36] has also been observed.  
This research provides support for the Polish version of the WHO-5 that may be useful 
for both clinical practice and empirical research in people with diabetes, because of both 
satisfactory psychometric properties and brief, positively worded content. Undoubtedly, free 
accessibility online of all existing language versions of the WHO-5 is a valuable asset which 
should contribute to the enhanced recognition of depression in people with diabetes. 
However, the validation of each version and determine optimal cut-off point are necessary for 
clinical practice, because health professionals have to be sure that any employed screening 
instrument is adapted to the patient’s culture, language, and literacy abilities [23]. The main 
aim of this study is consistent with the general objective of INTERPRET-DD project, namely, 
to assess the specificity and sensitivity of depression screening instruments when used in 
people with Type 2 diabetes [33]. Additionally, changes in wellbeing can be monitored when 
evaluating ongoing treatment, with a difference of 10% indicating a significant change [54].  
Thus, the effectiveness of the WHO-5 as a screening tool for depression is not only 
derived from its psychometric properties. The results of this study allow us to recommend the 
WHO-5 as a suitable first-step screening instrument for likely depression. Obviously, the 
WHO-5 cannot be used as the only and sufficient tool for the diagnosis of depression. 
Professionals should keep in mind that screening instruments only enhance recognition and do 
not replace a full clinical test. The presence of clinically significant depressive symptoms has 
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to be verified by full clinical diagnostic process including structured psychiatric diagnostic 
interview [20]. 
The strength of this study is the comparison of the WHO-5 scores with a clinical 
diagnostic interview for depression (MINI). Secondly, the PHQ-9 was used in this study as it 
is based on the DSM-IV diagnostic criteria for depression, and simultaneously it is 
recommended and commonly used for depression screening in people with diabetes [23]. 
Additionally, our exploratory ROC analyses comparing the WHO-5 with the diagnosis for 
major depressive syndrome by MINI are consistent with previous research indicating that 
WHO-5 is a reliable and valid self-assessment screening tool for major depression in people 
with diabetes at a cut-off point of ≤12 [55].  
. Although the total sample of this project is large, this report is based on data 
collected only in Poland (N = 216). Nevertheless it is larger than the majority of previous 
similar studies [28],[29], [35], [56] and makes a significant contribution to the field. The other 
caveat is that the large majority of the participants was living in an urban rather than rural 
location. It may be important point with respect to the difference in accessibility methods of 
non-pharmacological treatment. However, the INTERPRET-DD study did not record any 
non-pharmacological treatments at baseline. Moreover, the study was undertaken in specialist 
clinics where the sample of patients may be varied from the wider diabetes population. For 
example, there may be an overestimate or underestimate of the severity of depressive 
symptoms. The other limitations of INTERPRET-DD study with respect to the possibility of 
comparing results with other countries are reported elsewhere [33]. 
5. CONCLUSIONS 
This study has demonstrated that the psychometric properties and suitability of the 
WHO-5 as a screening instrument for likely depression in Polish adults with type 2 diabetes 
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are very good. Additionally, this study provides further support for the recommended cut-off 
value of ≤12. We have provided empirical support for the utility of the WHO-5 which can be 
a useful tool for both clinical practice and future studies carried out among Polish people with 
diabetes.  
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Associations between  participants’ demographic and clinical characteristics with WHO-5 
scores (N=216) 
Note:  
a) Based on nonparametric The Kruskal-Wallis H Test because of unequal group sizes 











statistic p value 
Gender 
 Male (n = 100) 16.50 (6.36) 
t(214) = 1.29 = 0.20  Female (n = 116) 15.36 (6.61) 
 Total sample (N = 216) 15.97 (6.48) 
Education level 
 No formal (n = 0) - 
H(2) = 1.66a = 0.44 
 Some/completed primary school (n = 19) 16.56 (6.35) 
 Some/completed secondary school (n = 141) 15.48 (6.73) 
 
Higher education (college, post-
grad/professional) (n = 57) 
17.00 (6.48) 
Residence 
 Rural/village (n = 20) 14.20 (6.30) 
U = 1559.50b = 0.13 
 Urban (n = 196) 16.15 (6.49) 
Age 57.42 (7.32) r = 0.110 = 0.109 




The results of Principal Axis Factoring and factor loadings of the 5 WHO-5 items (N = 216) 




1. I have felt cheerful and in good spirits .834 
3. I have felt active and vigorous .819 
2. I have felt calm and relaxed .801 
5. My daily life has been filled with things that interest me .797 



















Accuracy of the WHO-5 cut-off values for detecting major depression (diagnosed with the 
MINI) in adults with type 2 diabetes for the Polish sample (N = 216) 
WHO-5 
raw score 















0,000 0,094 1,000 1,000 0,864 0,000 0,906 0,094 
≤1 0,188 1,000 1,000 0,877 0,000 0,813 0,188 
≤2 0,313 0,995 0,909 0,893 57,813 0,691 0,307 
≤3 0,406 0,995 0,929 0,906 75,156 0,597 0,401 
≤4 0,531 0,995 0,944 0,925 98,281 0,471 0,526 
≤5 0,594 0,995 0,950 0,934 109,844 0,408 0,588 
≤6 0,625 0,995 0,952 0,939 115,625 0,377 0,620 
≤7 0,719 0,978 0,852 0,953 33,242 0,287 0,697 
≤8 0,719 0,951 0,719 0,951 14,774 0,296 0,670 
≤9 0,781 0,930 0,658 0,961 11,118 0,235 0,711 
≤10 0,875 0,903 0,609 0,977 8,993 0,138 0,778 
≤11 0,906 0,892 0,592 0,982 8,383 0,105 0,798 
≤12 0,938 0,865 0,545 0,988 6,938 0,072 0,802 
≤13 0,969 0,822 0,484 0,993 5,431 0,038 0,790 
≤14 0,969 0,778 0,431 0,993 4,371 0,040 0,747 
≤15 1,000 0,697 0,364 1,000 3,304 0,000 0,697 
≤16 1,000 0,632 0,320 1,000 2,721 0,000 0,632 
≤17 1,000 0,551 0,278 1,000 2,229 0,000 0,551 
≤18 1,000 0,481 0,250 1,000 1,927 0,000 0,481 
≤19 1,000 0,405 0,225 1,000 1,682 0,000 0,405 
≤20 1,000 0,330 0,205 1,000 1,492 0,000 0,330 
≤21 1,000 0,232 0,184 1,000 1,303 0,000 0,232 
≤22 1,000 0,184 0,175 1,000 1,225 0,000 0,184 
≤23 1,000 0,141 0,168 1,000 1,164 0,000 0,141 
≤24 1,000 0,108 0,162 1,000 1,121 0,000 0,108 
≤25 1,000 0,000 0,147 1,000 1,000 0,000 0,000 
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